{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:01:09Z","timestamp":1791547269059,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010745","name":"Norske Legeforening","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"Universitetet i Oslo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jacl.2019.01.010","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T05:37:33Z","timestamp":1548826653000},"page":"279-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2321-2490","authenticated-orcid":false,"given":"Martin P.","family":"Bogsrud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5057-8658","authenticated-orcid":false,"given":"Asgeir","family":"Gr\u00e6sdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisle","family":"Langslet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hovland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Erik","family":"Arnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv J.","family":"Mundal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Retterst\u00f8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Wium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8674-9703","authenticated-orcid":false,"given":"Kirsten B.","family":"Holven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jacl.2019.01.010_bib1","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"45","key":"10.1016\/j.jacl.2019.01.010_bib2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jacl.2019.01.010_bib3","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/eurheartj\/ehv602","article-title":"Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death","volume":"37","author":"Krogh","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacl.2019.01.010_bib4","doi-asserted-by":"crossref","first-page":"e001236","DOI":"10.1161\/JAHA.114.001236","article-title":"Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010","volume":"3","author":"Mundal","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.jacl.2019.01.010_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2047487316676135","article-title":"Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013","volume":"24","author":"Mundal","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"36","key":"10.1016\/j.jacl.2019.01.010_bib6","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacl.2019.01.010_bib7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jacl.2019.01.010_bib8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jacl.2015.08.008","article-title":"Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood","volume":"9","author":"Langslet","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2019.01.010_bib9","doi-asserted-by":"crossref","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jacl.2019.01.010_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"issue":"9965","key":"10.1016\/j.jacl.2019.01.010_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacl.2019.01.010_bib12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacl.2017.09.003","article-title":"Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Hovingh","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2019.01.010_bib13","first-page":"76","article-title":"Lipoprotein (a): structure, pathophysiology and clinical implications","volume":"103","author":"Maranhao","year":"2014","journal-title":"Arq Bras Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2019.01.010_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacl.2019.01.010_bib15","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jacl.2019.01.010_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2019.01.010_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/joim.12335","article-title":"Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia","volume":"278","author":"Vongpromek","year":"2015","journal-title":"J Intern Med"},{"issue":"19","key":"10.1016\/j.jacl.2019.01.010_bib18","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2019.01.010_bib19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.atherosclerosis.2011.02.007","article-title":"Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia","volume":"216","author":"Nenseter","year":"2011","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.jacl.2019.01.010_bib20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.jacl.2019.01.010_bib21","first-page":"60","article-title":"Reproducibility and validity of a short food questionnaire for the assessment of dietary habits","volume":"12","author":"Svilaas","year":"2002","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"11","key":"10.1016\/j.jacl.2019.01.010_bib22","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9601","key":"10.1016\/j.jacl.2019.01.010_bib23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacl.2019.01.010_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"17","key":"10.1016\/j.jacl.2019.01.010_bib25","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.jacl.2019.01.010_bib26","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.jacl.2019.01.010_bib27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/eurheartj\/ehx197","article-title":"Can we afford not to screen for FH?","volume":"38","author":"Stoekenbroek","year":"2017","journal-title":"Eur Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419300273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419300273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:33:53Z","timestamp":1761831233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287419300273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1933287419300273"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2019.01.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2019.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}